250 related articles for article (PubMed ID: 25704355)
1. Novel therapies for FSGS: preclinical and clinical studies.
Malaga-Dieguez L; Bouhassira D; Gipson D; Trachtman H
Adv Chronic Kidney Dis; 2015 Mar; 22(2):e1-6. PubMed ID: 25704355
[TBL] [Abstract][Full Text] [Related]
2. Protecting Podocytes: A Key Target for Therapy of Focal Segmental Glomerulosclerosis.
Campbell KN; Tumlin JA
Am J Nephrol; 2018; 47 Suppl 1(Suppl 1):14-29. PubMed ID: 29852493
[TBL] [Abstract][Full Text] [Related]
3. Investigational drugs in development for focal segmental glomerulosclerosis.
Trachtman H
Expert Opin Investig Drugs; 2017 Aug; 26(8):945-952. PubMed ID: 28707483
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances in Treatments of Primary Focal Segmental Glomerulosclerosis in Children.
Han KH; Kim SH
Biomed Res Int; 2016; 2016():3053706. PubMed ID: 27195285
[TBL] [Abstract][Full Text] [Related]
5. Emerging drugs for treatment of focal segmental glomerulosclerosis.
Trachtman H
Expert Opin Emerg Drugs; 2020 Sep; 25(3):367-375. PubMed ID: 32729368
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group.
Joy MS; Gipson DS; Powell L; MacHardy J; Jennette JC; Vento S; Pan C; Savin V; Eddy A; Fogo AB; Kopp JB; Cattran D; Trachtman H
Am J Kidney Dis; 2010 Jan; 55(1):50-60. PubMed ID: 19932542
[TBL] [Abstract][Full Text] [Related]
7. A prospective study of collapsing focal segmental glomerulosclerosis.
Raja R; Nada R; Yadav AK; Kumar A; Goyal A; Kumar V; Rathi M; Kohli HS; Gupta KL; Sakhuja V; Jha V
Ren Fail; 2016 Jul; 38(6):894-8. PubMed ID: 27266801
[TBL] [Abstract][Full Text] [Related]
8. Secondary Focal Segmental Glomerulosclerosis: From Podocyte Injury to Glomerulosclerosis.
Kim JS; Han BG; Choi SO; Cha SK
Biomed Res Int; 2016; 2016():1630365. PubMed ID: 27088082
[TBL] [Abstract][Full Text] [Related]
9. HIV-associated nephropathy: experimental models.
Avila-Casado C; Fortoul TI; Chugh SS
Contrib Nephrol; 2011; 169():270-285. PubMed ID: 21252526
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group.
Trachtman H; Vento S; Herreshoff E; Radeva M; Gassman J; Stein DT; Savin VJ; Sharma M; Reiser J; Wei C; Somers M; Srivastava T; Gipson DS
BMC Nephrol; 2015 Jul; 16():111. PubMed ID: 26198842
[TBL] [Abstract][Full Text] [Related]
11. Focal and segmental glomerulosclerosis: does prognosis vary with the variants?
Swarnalatha G; Ram R; Ismal KM; Vali S; Sahay M; Dakshinamurty KV
Saudi J Kidney Dis Transpl; 2015 Jan; 26(1):173-81. PubMed ID: 25579744
[TBL] [Abstract][Full Text] [Related]
12. Current and emerging treatments for idiopathic focal and segmental glomerulosclerosis in adults.
Ponticelli C; Graziani G
Expert Rev Clin Immunol; 2013 Mar; 9(3):251-61. PubMed ID: 23445199
[TBL] [Abstract][Full Text] [Related]
13. The role of podocyte injury in the pathogenesis of focal segmental glomerulosclerosis.
Schwartz MM
Ren Fail; 2000 Nov; 22(6):663-84. PubMed ID: 11104157
[TBL] [Abstract][Full Text] [Related]
14. Podocyte and endothelial injury in focal segmental glomerulosclerosis: an ultrastructural analysis.
Taneda S; Honda K; Ohno M; Uchida K; Nitta K; Oda H
Virchows Arch; 2015 Oct; 467(4):449-58. PubMed ID: 26266776
[TBL] [Abstract][Full Text] [Related]
15. Novel unbiased assay for circulating podocyte-toxic factors associated with recurrent focal segmental glomerulosclerosis.
Kachurina N; Chung CF; Benderoff E; Babayeva S; Bitzan M; Goodyer P; Kitzler T; Matar D; Cybulsky AV; Alachkar N; Torban E
Am J Physiol Renal Physiol; 2016 May; 310(10):F1148-56. PubMed ID: 26719363
[TBL] [Abstract][Full Text] [Related]
16. Towards a biological characterization of focal segmental glomerulosclerosis.
Devarajan P; Spitzer A
Am J Kidney Dis; 2002 Mar; 39(3):625-36. PubMed ID: 11877584
[TBL] [Abstract][Full Text] [Related]
17. Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design.
Trachtman H; Vento S; Gipson D; Wickman L; Gassman J; Joy M; Savin V; Somers M; Pinsk M; Greene T
BMC Nephrol; 2011 Feb; 12():8. PubMed ID: 21310077
[TBL] [Abstract][Full Text] [Related]
18. Regulation of TRPC6 ion channels in podocytes - Implications for focal segmental glomerulosclerosis and acquired forms of proteinuric diseases.
Szabó T; Ambrus L; Zákány N; Balla G; Bíró T
Acta Physiol Hung; 2015 Sep; 102(3):241-51. PubMed ID: 26551740
[TBL] [Abstract][Full Text] [Related]
19. The treatment of primary focal segmental glomerulosclerosis.
Korbet SM
Ren Fail; 2000 Nov; 22(6):685-96. PubMed ID: 11104158
[TBL] [Abstract][Full Text] [Related]
20. Advanced therapeutics in focal and segmental glomerulosclerosis.
Liu Y; Shi Y; Ren R; Xie J; Wang W; Chen N
Nephrology (Carlton); 2018 Oct; 23 Suppl 4():57-61. PubMed ID: 30298667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
